U.S. End Stage Renal Disease Market Size & Outlook

The end stage renal disease market in the United States is expected to reach a projected revenue of US$ 37,790.2 million by 2030. A compound annual growth rate of 13.1% is expected of the United States end stage renal disease market from 2024 to 2030.
Revenue, 2023 (US$M)
$15,950.6
Forecast, 2030 (US$M)
$37,790.2
CAGR, 2024 - 2030
13.1%
Report Coverage
U.S.

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

U.S. end stage renal disease market, 2018-2030 (US$M)

U.S. end stage renal disease market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

U.S. end stage renal disease market highlights

  • The U.S. end stage renal disease market generated a revenue of USD 15,950.6 million in 2023 and is expected to reach USD 37,790.2 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 13.1% from 2024 to 2030.
  • In terms of segment, dialysis was the largest revenue generating treatment type in 2023.
  • Dialysis is the most lucrative treatment type segment registering the fastest growth during the forecast period.


End stage renal disease market data book summary

Market revenue in 2023USD 15,950.6 million
Market revenue in 2030USD 37,790.2 million
Growth rate13.1% (CAGR from 2023 to 2030)
Largest segmentDialysis
Fastest growing segmentDialysis
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationTransplant, Dialysis
Key market players worldwideNipro Corp, Fresenius SE & Co KGaA, Baxter International Inc, Medtronic PLC, B. Braun, BD, Asahi Kasei Corp, Cantel Medical, Nikkiso Co Ltd, JMS Support Japan


Other key industry trends

  • In terms of revenue, U.S. accounted for 14.3% of the global end stage renal disease market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. end stage renal disease market is projected to lead the regional market in terms of revenue in 2030.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 37,790.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

End Stage Renal Disease Market Companies

Name Profile # Employees HQ Website
JMS Support Japan View profile 11-50 Tokyo, Tokyo, Japan, Asia https://jms-support.jp
Cantel Medical View profile 1001-5000 Little Falls, New Jersey, United States, North America http://www.cantelmedical.com
BD View profile 10001+ Franklin Lakes, New Jersey, United States, North America https://www.bd.com
Nikkiso Co Ltd View profile 8529 4-20-3, Ebisu, Shibuya-ku, Tokyo, Japan, 150-6022 http://www.nikkiso.co.jp
Nipro Corp View profile 39713 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 http://www.nipro.co.jp
B. Braun View profile 10001+ Chapeltown, Sheffield, United Kingdom, Europe https://www.bbraun.co.uk
Asahi Kasei Corp View profile 48897 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, Japan, 101-8101 http://www.asahi-kasei.co.jp
Fresenius SE & Co KGaA View profile 193865 Else-Kroener-Strasse 1, Bad Homburg, HE, Germany, 61352 https://www.fresenius.com
Medtronic PLC View profile 95000 Lower Hatch Street, 20 On Hatch, Dublin, Ireland, 2 https://www.medtronic.com
Baxter International Inc View profile 60000 One Baxter Parkway, Deerfield, IL, United States, 60015 https://www.baxter.com

U.S. end stage renal disease market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to end stage renal disease market will help companies and investors design strategic landscapes.


Dialysis was the largest segment with a revenue share of 78.13% in 2023. Horizon Databook has segmented the U.S. end stage renal disease market based on transplant, dialysis covering the revenue growth of each sub-segment from 2018 to 2030.


As per the National Kidney Foundation, CKD has affected around 37 million people in the U.S. CKD is more common in women as compared to that in men.

Furthermore, as per the same source, in 2017, more than 500,000 patients have undergone dialysis and more than 200,000 people are living with a kidney transplant.

Moreover, Medicare cost of the people with all the stages of CKD in 2017 was around USD 120 billion. In 2017, Medicare spent USD 84 billion on people with CKD and USD 36 billion on people with End Stage Kidney Disease (ESKD).

Reasons to subscribe to U.S. end stage renal disease market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. end stage renal disease market databook

  • Our clientele includes a mix of end stage renal disease market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. end stage renal disease market , including forecasts for subscribers. This country databook contains high-level insights into U.S. end stage renal disease market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

U.S. end stage renal disease market size, by dialysis, 2018-2030 (US$M)

U.S. End Stage Renal Disease Market Outlook Share, 2023 & 2030 (US$M)

U.S. end stage renal disease market size, by dialysis, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online